DURHAM, N.C., April 11, 2023 (GLOBE NEWSWIRE) — Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced it has completed enrollment of a Phase 3 trial in hemodialysis access. The “V007 Trial” is designed to assess the efficacy and…Read More
Humacyte Completes Enrollment in Phase 3 Trial of Human Acellular Vessel HAV for Hemodialysis Access in EndStage Renal Disease Patients
